Compare Noble Corporation plc (NE) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Noble Corporation plc vs Twist Bioscience Corp — how do they compare? Noble Corporation plc trades at $45.83 (market cap $7.26B), while Twist Bioscience Corp trades at $124.3 (market cap $8.26B). The key difference: Noble Corporation plc and Twist Bioscience Corp are close in size by market cap, and Noble Corporation plc pays a 4.4% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| NE | TWST | |
|---|---|---|
Market Cap | $7.26B | $8.26B |
Sector | Technology | Health |
52-Week High | $54.37 | $153.10 |
52-Week Low | $26.70 | $24.16 |
Enterprise Value | $8.69B | $8.18B |
Dividend Yield | 4.4% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Noble Corporation (NE) trades at $45.89, up 0.61% on the day, with a bullish technical signal from moving averages. The stock shows mixed earnings performance, beating estimates in Q1 2026 but missing in Q4 2025 and Q2 2026. Revenue declined to $3.1B in 2026 from $3.3B in 2025, with net income falling to $150M. Analyst consensus is a 'Buy' with a $46.00 price target, though legal investigations have surfaced in recent news.
Outlook is cautious due to earnings volatility and legal overhangs, but positive cash flow and a dividend payment offer some support. Risks include potential securities litigation and competitive pressures in the energy sector. The stock presents a speculative opportunity with balanced analyst sentiment.
Twist Bioscience (TWST) trades at $128.06, up 2.68% with a bearish technical signal despite recent AI-driven momentum. The company shows strong revenue growth (2025: $377M, 2026: $432M projected) but continues to report significant losses with negative net margins. Recent news highlights AI partnerships and a $300M stock offering, while analyst consensus remains predominantly bullish with 78.6% buy ratings.
TWST presents a high-risk growth opportunity with accelerating revenue but persistent profitability challenges. The stock's valuation appears stretched at P/S of 18.09, requiring successful execution on AI initiatives and path to EBITDA breakeven. Key risks include cash burn, competitive pressures, and dependence on emerging AI-driven drug discovery markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Noble Corporation plc
Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.
Read more on NE →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
